Diagnosis of pancreatic cancer using serum proteomic profiling

Neoplasia

Volumn 6, Issue 5, 2004, Pages 674-686

  Bhattacharyya, Sudeepa ^a   Siegel, Eric R ^a   Petersen, Gloria M ^b   Chari, Suresh T ^b   Suva, Larry J ^a   Haun, Randy S ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b MAYO CLINIC ROCHESTER   (United States)

Author keywords

Early detection; Mass spectrometry; Proteomics; SELDI; Surface enhanced laser desorption ionization

Indexed keywords

ANION EXCHANGE RESIN; BIOLOGICAL MARKER; PROTEOME;

ADULT; AGED; ALGORITHM; ANION EXCHANGE; ARTICLE; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DESORPTION; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; IONIZATION; LASER; LOGISTIC REGRESSION ANALYSIS; MALE; MASS SPECTROMETRY; MULTIVARIATE ANALYSIS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEOMICS; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 6944239964     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04262     Document Type: Article

References (34)

1. Ulrich CD II (2000). Growth factors, receptors, and molecular alterations in pancreatic cancer. Med Clin North Am 84, 697-705.
2. Sakorafas GH, Tsiotou AG, and Tsiotos GG (2000). Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat Rev 26, 29-52.
3. Mack TM, Yu MC, Hanisch R, and Henderson BE (1986). Pancreas cancer and smoking, beverage consumption, and past medical history. J Natl Cancer Inst 76, 49-60.
4. Lynch HT, Fitzsimmons ML, Smyrk TC, Lanspa SJ, Watson P, McClellan J, and Lynch JF (1990). Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. Am J Gastroenterol 85, 54-60.
5. Pietri F and Clavel F (1991). Occupational exposure and cancer of the pancreas: a review. Br J Ind Med 48, 583-587.
6. What You Need to Know About Cancer of the Pancreas (2001). National Cancer Institute, Bethesda, MD.
7. Hawes RH, Xiong Q, Waxman I, Chang KJ, Evans DB, and Abbruzzese JL (2000). A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol 95, 17-31.
8. Murr MM, Sarr MG, Oishi AJ, and van Heerden JA (1994). Pancreatic cancer. CA Cancer J Clin 44, 304-318.
9. Rosewicz S and Wiedenmann B (1997). Pancreatic carcinoma. Lancet 349, 485-489.
10. Moossa AR and Gamagami RA (1995). Diagnosis and staging of pancreatic neoplasms. Surg Clin North Am 75, 871-890.
11. Posner MR and Mayer RJ (1994). The use of serological tumor markers in gastrointestinal malignancies. Hematol/Oncol Clin North Am 8, 533-553.
12. Gullo L (1994). CA 19-9: the Italian experience. Pancreas 9, 717-719.
13. Yasue M, Sakamoto J, Teramukai S, Morimoto T, Yasui K, Kuno N, Kurimoto K, and Ohashi Y (1994). Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer. Pancreas 9, 735-740.
14. Satake K and Takeuchi T (1994). Comparison of CA 19-9 with other tumor markers in the diagnosis of cancer of the pancreas. Pancreas 9, 720-724.
15. Satake K, Takeuchi T, Homma T, and Ozaki H (1994). CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas 9, 703-706.
16. Steinberg WM, Gelfand R, Anderson KK, Glenn J, Kurtzman SH, Sindelar WF, and Toskes PD (1986). Comparison of the sensitivity and specificity of the CA19-9 carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 90, 343-349.
17. Steinberg W (1990). The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 85, 350-355.
18. Hasegawa T, Isobe K, Tsuchiya Y, Oikawa S, Nakazato H, Nakashima I, and Shimokata K (1993). Nonspecific crossreacting antigen (NCA) is a major member of the carcinoembryonic antigen (CEA) - related gene family expressed in lung cancer. Br J Cancer 67, 58-65.
19. Wulfkuhle JD, Liotta LA, and Petricoin EF III (2003). Proteomic applications for the early detection of cancer. Nat Rev Cancer 3, 267-275.
20. Srinivas PR, Srivastava S, Hanash S, and Wright JR (2001). Proteomics in early detection of cancer. Clin Chem 47, 1901-1911.
21. Negm RS, Verma M, and Srivastava S (2002). The promise of biomarkers in cancer screening and detection. Trends Mol Med 8, 288-293.
22. Chambers G, Lawrie L, Cash P, and Murray GI (2000). Proteomics: a new approach to the study of disease. J Pathol 192, 280-288.
23. Merchant M and Weinberger SR (2000). Recent advancements in surface-enhanced laser desorption/ionization time of flight-mass spectrometry. Electrophoresis 21, 1164-1167.
24. Issaq HJ, Veenstra TD, Conrads TP, and Felschow D (2002). The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commum 292, 587-592.
25. Watkins B, Szaro R, Ball S, Knubovets T, Briggman J, Hlavaty JJ, Kusinitz F, Stieg A, and Wu Y-I (2001), Detection of early-stage cancer by serum protein analysis. Am Lab, 32-36.
26. Li J, Zhang Z, Rosenzweig J, Wang YY, and Chan DW (2002). Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48, 1296-1304.
27. Poon TCW, Yip T-T, Chan ATC, Yip C, Yip V, Mok TSK, Lee CCY, Ho TWT, Leung SKW, and Johnson PJ (2003). Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem 49, 752-760.
28. Petricoin EF III, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, and Liotta LA (2002). Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577.
29. Rai AJ, Zhang Z, Rosenweig J, Shih T, Pham ET, Fung LJ, and Sokoll DW (2002). Proteomic approaches to tumor marker discovery: identification of biomarkers for ovarian cancer. Arch Pathol Lab Med 126, 1518-1526.
30. Adam B-L, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer Y, Yasui Z, and Feng GL (2002). Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62, 3609-3614.
31. Bañez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam B-L, McLeod DG, and Srivastava S (2003). Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 170, 442-446.
32. Westfall PH and Young SS (1993). Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment. John Wiley and Sons, Inc., New York, NY.
33. Breiman L, Friedman J, Olshen RA, and Stone CJ (1984). Classification and Regression Trees. Wadsworth International Group, Belmont, CA.
34. Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, and Goggins M (2004). Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 10, 860-868.